CT1812 a new drug for Alzheimer's disease

What is it about?

Background: Alzheimer’s disease (AD) is becoming more common as people live longer. This illness is marked by memory loss, confusion, and difficulty thinking, gradually worsening over time. For years, researchers have focused on treating AD by targeting a substance called amyloid-beta (Aβ), which builds up in the brains of people with Alzheimer’s and is believed to harm brain cells. Many treatments have been developed to try to stop or remove Aβ, including antibodies designed to target it. Unfortunately, these treatments have had mixed results and, in some cases, caused concerning side effects. Recently, researchers discovered that Aβ binds to a particular protein in the brain known as the sigma-2 receptor (σ-2R) or TMEM97. This receptor might play a role in the development of AD because it binds with Aβ clumps (or oligomers), possibly making it easier for Aβ to harm brain cells. Because of this connection, some scientists now believe that blocking or interfering with the sigma-2 receptor could help prevent Aβ from sticking around in the brain and causing damage. One potential treatment is CT1812, a drug that works against the sigma-2 receptor. It aims to block Aβ from binding to the receptor, which could help remove or reduce Aβ in the brain. Early studies in animals have shown positive results, and now CT1812 is being tested in humans in clinical trials. Objective: This study reviews all available research on the safety and effectiveness of CT1812 in treating AD, especially its ability to reduce Aβ in the brain and potentially help with memory and thinking. Methods: Researchers searched medical databases like PubMed, Scopus, and Google Scholar, as well as clinical trial websites, for studies conducted up to August 2023. They looked for information on CT1812’s effects, side effects, and any signs that it could help with symptoms of AD. Results: So far, CT1812 appears to be safe when taken at doses up to 840 mg, with only mild side effects reported, such as nausea or headaches. In clinical studies, CT1812 has shown promise in reducing the amount of Aβ in the brain, which matches earlier animal study results. Some studies have also looked at how CT1812 affects brain connections and brain function in AD patients, which is encouraging. However, there is limited information on whether CT1812 improves memory or thinking skills directly—only one study so far has included cognitive testing, and it was a secondary focus. Conclusions: CT1812 is a promising new approach to targeting Aβ in the brain, with early evidence suggesting it may be safe and effective in reducing harmful Aβ buildup. However, it’s still uncertain whether reducing Aβ alone will be enough to slow down or stop memory loss and other symptoms of AD. More long-term studies are needed to understand if CT1812 can truly improve quality of life for people with AD. Fortunately, several longer-term trials are currently underway, which may soon provide more answers.

Featured Image

Photo by Myriam Zilles on Unsplash

Photo by Myriam Zilles on Unsplash

Why is it important?

This study is important because Alzheimer's disease (AD) affects millions of people worldwide, with cases increasing as the population ages. Current treatments for AD only address symptoms temporarily without stopping or reversing the brain damage caused by the disease. For decades, researchers have focused on reducing amyloid-beta (Aβ) deposits in the brain, a protein believed to play a significant role in AD progression. However, existing Aβ-targeting treatments have had limited success, and some have raised serious safety concerns. CT1812 offers a new approach by targeting a specific receptor in the brain, the sigma-2 receptor (σ-2R/TMEM97), which binds with Aβ and may contribute to its harmful effects on brain cells. By blocking this receptor, CT1812 may prevent Aβ from accumulating in the brain and might reduce the damage it causes. This could offer a different and potentially safer way to tackle Aβ in AD patients. If CT1812 proves effective, it could lead to a safer treatment option that directly addresses the underlying biology of AD, potentially slowing or even stopping memory loss and cognitive decline in affected individuals. Since AD has no cure and available therapies do not alter disease progression, finding new and effective treatments like CT1812 could significantly improve the quality of life for millions and reduce the impact of AD on patients, families, and healthcare systems. Additionally, this study is crucial because it adds to our understanding of the role of the sigma-2 receptor in AD and how targeting it might benefit patients. This could open doors to new research directions and treatment approaches for AD and other neurodegenerative diseases.